Suneva Medical, a privately-held aesthetics company, has selected Quinnova Pharmaceuticals, a premier provider of therapeutic skin and wound products in the United States, to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
"Quinnova has structured its unique delivery platforms to provide superior products that address a variety of skin conditions," said Jeffrey Day, Quinnova's president, CEO and founder. "As one of the most effective treatments for fine facial wrinkles, ReFissa strengthens our product portfolio, adding a coveted topical aesthetic solution to our portfolio and enhancing our value among healthcare professionals."
Quinnova to Co-Promote Refissa
Jun 6th, 2013
